EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer

Sara M Tolaney, Evandro de Azambuja iD, Kevin Kalinsky, Sherene Loi, Sung-Bae Kim, Clinton Yam iD, Bernardo Rapoport, Seock-Ah Im, Barbara Pistilli iD, Wassim Mchayleh, David W Cescon, Junichiro Watanabe und 9 weitere

New England Journal of Medicine · 22.01.2026 · 394 (4) · 354-366

DOI: 10.1056/nejmoa2508959 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 22.01.2026. Verfasst von Sara M Tolaney und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Triple Negative Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Gilead Sciences, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsTriple Negative Breast NeoplasmsImmunoconjugatesAdultAgedAged, 80 and overFemaleHumansMiddle AgedCamptothecinProgression-Free SurvivalImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorYoung Adult

Substanzen

Antibodies, Monoclonal, HumanizedCamptothecinpembrolizumabsacituzumab govitecanImmunoconjugatesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston.
  • Institut Jules Bordet, Hôpital Universitaire de Bruxelles and Université Libre de Bruxelles, Brussels.
  • Winship Cancer Institute, Emory University, Atlanta.
  • Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • University of Texas M.D. Anderson Cancer Center, Houston.

ORCID-Profile: Evandro de Azambuja, Clinton Yam, Barbara Pistilli

Förderung

  • Gilead Sciences, Inc

Zitieren

APA

Tolaney, S. M., de Azambuja, E., Kalinsky, K., Loi, S., Kim, S. B., Yam, C., Rapoport, B., Im, S. A., Pistilli, B., Mchayleh, W., Cescon, D. W., Watanabe, J., Bañuelas, M. A. L., Freitas-Junior, R., Salvador Bofill, J., Afshari, M., Gary, D., Wang, L., Lai, C., …, & ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 394(4), 354-366. https://doi.org/10.1056/nejmoa2508959

Vancouver

Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, et al. Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2026;394(4):354-366. doi:10.1056/nejmoa2508959

BibTeX
@article{Tolaney2026,
  author = {Tolaney, Sara M and de Azambuja, Evandro and Kalinsky, Kevin and Loi, Sherene and Kim, Sung-Bae and Yam, Clinton and Rapoport, Bernardo and Im, Seock-Ah and Pistilli, Barbara and Mchayleh, Wassim and Cescon, David W and Watanabe, Junichiro and Bañuelas, Manuel Alejandro Lara and Freitas-Junior, Ruffo and Salvador Bofill, Javier and Afshari, Maryam and Gary, Dianna and Wang, Lu and Lai, Catherine and Schmid, Peter and ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators, ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators},
  title = {Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {4},
  pages = {354--366},
  doi = {10.1056/nejmoa2508959}
}
Kostenlos starten →